ArticleMolecular biology reports2026
The relationship of cucurbitacin E with epileptic seizures, circadian rhythm, and genetics in a pentylenetetrazole-induced mouse model of epilepsy.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEpilepsy is a chronic neurological disorder characterized by recurrent seizures resulting from abnormal neuronal electrical activity. Increasing evidence suggests that circadian clock dysfunction contributes to seizure susceptibility and neuronal excitability. Melatonin, a major regulator of circadian rhythm, possesses antioxidant and neuroprotective properties that may influence seizure regulation. Cucurbitacin E (CuE), a triterpenoid compound with potent antioxidant and anti-inflammatory activities, has emerged as a potential therapeutic agent targeting circadian and oxidative pathways. This study investigated the effects of CuE on seizure activity, oxidative balance, melatonin levels, and circadian clock gene expression in a pentylenetetrazol (PTZ)-induced epilepsy model.
methodsEighteen male C57BL/6 mice were randomly assigned to control, PTZ, and PTZ + CuE groups (baseline n = 6/group). PTZ (35 mg/kg/day, i.p.) was administered every other day for 12 days, while CuE (0.5 mg/kg/day, i.p.) was administered 30 min after PTZ injections. Two animals were excluded during the study, resulting in final group sizes of n = 6, n = 5, and n = 5, respectively. Seizure severity was assessed using Racine scoring, and locomotor activity was monitored using the LABORAS system with manual seizure validation. Serum melatonin, total antioxidant status (TAS), total oxidant status (TOS), and circadian clock gene expression (PER1, CRY1, CLOCK, BMAL1, RORA, and REV-ERBα) were analyzed.
resultsPTZ significantly increased seizure severity, oxidative stress, melatonin levels, and disrupted clock gene expression, whereas CuE markedly reduced seizures, improved oxidative balance, normalized melatonin levels, and partially restored circadian gene expression. Significant correlations were identified between melatonin levels and multiple clock genes.
conclusionThese findings demonstrate that CuE exerts anticonvulsant effects through integrated chronomodulatory and antioxidant mechanisms, supporting its potential as a multi-target therapeutic strategy for epilepsy management.
Indexed as
Identifiers
42201503What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.